Literature DB >> 16258153

A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Zhong Chen1, Bonnie Issa, Shiang Huang, Emily Aston, Jia Xu, Margaret Yu, Arthur R Brothman, Martha Glenn.   

Abstract

Multiple myeloma (MM) is a malignancy of differentiated B lymphocytes and has remained an incurable disease. Chromosomal abnormalities are among the most important prognostic parameters for MM. Cytoplasm immunoglobulin-enhanced interphase fluorescent in situ hybridization (FISH) has been a standard cell-targeting method for identifying genomic aberrations in MM. We have developed another cell-targeting approach by using CD138 magnetic microbeads to sort plasma cells for FISH analysis. The FISH panel consisted of four probes targeting RB-1, D13S319, immunoglobulin H, and p53 loci. We reviewed the FISH and conventional cytogenetic results of 60 patients with MM. The present cell-targeting approach in conjunction with the FISH probe panel was more sensitive than FISH performed on untargeted cells in detecting prognostically significant genomic aberrations (72 versus 24%, P = 0.0016). The frequencies of genomic abnormalities identified were similar to previously reported data obtained with the standard cell-targeting method. Therefore, our cell-targeting approach and FISH panel reliably detect prognostically important genomic abnormalities in MM and are potentially suitable for widespread use.

Entities:  

Mesh:

Year:  2005        PMID: 16258153      PMCID: PMC1867553          DOI: 10.1016/S1525-1578(10)60588-0

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  33 in total

1.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.

Authors:  N Zojer; R Königsberg; J Ackermann; E Fritz; S Dallinger; E Krömer; H Kaufmann; L Riedl; H Gisslinger; S Schreiber; R Heinz; H Ludwig; H Huber; J Drach
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

2.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.

Authors:  H Avet-Loiseau; C Brigaudeau; N Morineau; P Talmant; J L Laï; A Daviet; J Y Li; V Praloran; M J Rapp; J L Harousseau; T Facon; R Bataille
Journal:  Genes Chromosomes Cancer       Date:  1999-01       Impact factor: 5.006

3.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Authors:  H Avet-Loiseau; J Y Li; T Facon; C Brigaudeau; N Morineau; F Maloisel; M J Rapp; P Talmant; F Trimoreau; A Jaccard; J L Harousseau; R Bataille
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

4.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

Authors:  T Facon; H Avet-Loiseau; G Guillerm; P Moreau; F Geneviève; M Zandecki; J L Laï; X Leleu; J P Jouet; F Bauters; J L Harousseau; R Bataille; J Y Mary
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

Authors:  H Avet-Loiseau; T Facon; A Daviet; C Godon; M J Rapp; J L Harousseau; B Grosbois; R Bataille
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  PHA/IL2: an efficient mitogen cocktail for cytogenetic studies of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  R Morgan; Z Chen; K Richkind; S Roherty; J Velasco; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1999-03

Review 7.  Advances in the biology and therapeutic management of multiple myeloma.

Authors:  H Kaufmann; E Urbauer; J Ackermann; H Huber; J Drach
Journal:  Ann Hematol       Date:  2001-08       Impact factor: 3.673

8.  High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.

Authors:  J Shaughnessy; E Tian; J Sawyer; K Bumm; R Landes; A Badros; C Morris; G Tricot; J Epstein; B Barlogie
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

9.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Authors:  Hervé Avet-Loiseau; Thierry Facon; Bernard Grosbois; Florence Magrangeas; Marie-José Rapp; Jean-Luc Harousseau; Stéphane Minvielle; Régis Bataille
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

10.  Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.

Authors:  Rafael Fonseca; David Harrington; Martin M Oken; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Emily A Blood; S Vincent Rajkumar; Neil E Kay; Brian Van Ness; Philip R Greipp
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

View more
  2 in total

1.  Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.

Authors:  James R Cook; Marybeth Hartke; James Pettay; Raymond R Tubbs
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

2.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.